Jump to Main Content

Programs

ASH Poster Walks

ASH Poster Walk on Clinical Trials In Progress


December 16, 2021, 10:00 a.m. - 11:00 a.m.
Virtual Meeting Platform Only

Please view the recorded poster presentations prior to attending this virtual session:

The Trials in Progress (TiP) category is for abstracts specifically describing clinical trial design without presentation of results. This abstract category is now in its 3rd year at ASH and has seen growth in the number of submissions. The purpose of the Poster Walk is to discuss innovative aspects of the trial design between the presenter, key opinion leaders, and others attending. Innovative aspects may include statistical modeling, unique endpoints, biomarkers, non-traditional control groups, and approaches for enrolling diverse participants, as well as other approaches used to streamline the clinical trial. Posters from any category below could be included and are selected from those designated as TiP abstracts by the authors at submission.

The following abstracts will be featured in this session:

Trial in Progress: A Multicenter, Open Label, Randomized, Phase III Study of Asciminib (80 mg Once Daily) Vs Investigator-Selected TKI in Newly Diagnosed Adult Patients with Chronic Myeloid Leukemia in Chronic Phase, Jorge Cortes

Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Evolve CLL/SLL Study (SWOG S1925; NCT#04269902), Deborah Stephens

Effects of the COVID-19 Pandemic on Caregivers of Young Children with Sickle Cell Disease Enrolled in the Engage-HU Trial, Anna Hood

A Phase 3, Randomized, Double-Blinded Study of Four-Factor Prothrombin Complex Concentrate in Patients with Acute Major Bleeding on Direct Oral Anticoagulant Therapy with Factor Xa Inhibitor: The Lex-210 Study, Ravi Sarode

Organizer:

Alan E. Mast, MD,PhD
Blood Center of Wisconsin
Milwaukee, WI

Grzegorz S. Nowakowski, MD
Mayo Clinic
Rochester, MN

back to top

ASH Poster Walk on Diversity, Equity, and Inclusion in Hematologic Malignancies and Cell Therapy


December 16, 2021, 5:00 p.m. - 6:00 p.m.
Virtual Meeting Platform Only

Please view the recorded poster presentations prior to attending this virtual session:

Although hematopoietic cell transplantation and cellular therapies (TCT) are potentially curative therapies for high-risk or advanced hematologic malignancies, disparities impact the provision of care for TCT candidates and recipients. The ASH Poster Walk on Diversity, Equity, and Inclusion in Hematologic Malignancies and Cell Therapy will highlight work being done to investigate and address factors which impact the provision of care across malignant hematology for racialized patients, those of lower socio-economic status, or other vulnerable groups. The walk will also feature work being done to make the field more inclusive for patients and practitioners across race, ethnicity, sexual orientation, gender identity, socioeconomic status, nationality, and disability. Review of this research will improve participant understanding of disparities in malignant hematology and TCT, which is necessary to identify specific patient groups at risk for compromised care. This information is a pre-requisite to enhance outcomes and care delivery. The poster walk will also serve to connect stakeholders interested in Diversity, Equity, and Inclusion (DEI) in malignant hematology and TCT, and will facilitate discussions on the state of DEI research in the field. We will discuss how such efforts can support critically important work to diversify patient populations, mitigate barriers to care, and maximize the equitable provision of optimal TCT for less or under-privileged groups.

The following abstracts will be featured in this session:

Saving Lives with Pride: Development and Evaluation of Multimedia Resources to Engage Gay, Bisexual, and Queer Men in Canada As Stem Cell Donors, Rupal Hatkar

Racial Disparities in the Diagnostic Evaluation of Multiple Myeloma, Lucia Notardonato

Enrolment and Outcomes of Ethnic Minorities with Multiple Myeloma Treated in UK Myeloma Research Alliance (UK-MRA) Clinical Trials over 18 Years, Rakesh Popat

Acute Myeloid Leukemia (AML) Hospitalizations: Racial Disparity in Outcomes of Patients with Comorbidities, Sara Taveras Alam

Gender Disparities in Myelodysplastic Syndromes: Phenotype, Genotype, and Outcomes, Sara Tinsley-Vance

Ethnicity, Nativity and Outcomes in Burkitt Lymphoma Among US Hispanics: Texas and Florida State Database Study, Snegha Ananth

Organizer:

Warren Fingrut, MD
Memorial Sloan Kettering Cancer Center
New York, 

Juliet N Barker, MBBS
Memorial Sloan Kettering Cancer Center
New York, NY

Samer Al Hadidi, MD,MSc
Winthrop P. Rockefeller Cancer Institute University of Arkansas for Medical Sciences
Houston, TX

back to top

ASH Poster Walk on Emerging Research in Immunotherapies


December 16, 2021, 5:00 p.m. - 6:00 p.m.
Virtual Meeting Platform Only

Please view the recorded poster presentations prior to attending this virtual session:

Immunotherapies in Hematology is a rapidly evolving area in hematology. Cutting-edge basic research and clinical findings are presented each year at ASH with broad interest. Understanding of basic immunology is essential to unlock the underpinnings of hematologic disease. Likewise, immunotherapy has revolutionized treatment for patients and is rapidly being applied to malignant and non-malignant diseases to improve outcomes. Emphasis on both basic-translational immunology and applications of immunotherapy is central to improved care in hematologic diseases as fundamentals of immunology, including B/T-cell and thymus function, has broad applications to hematopoietic stem cell transplantation, transfusion medicine, cellular therapy, and novel immune based therapies.

The ASH Poster Walk on Emerging Research in Immunotherapies will present six posters from all fields that are related to “Immunotherapy”: basic-translational research, and clinical research; malignant, and non-malignant. The poster walk will prioritize concept novelty and contribution to the field. The session will also represent junior investigators,  gender diversity, institutional diversity, international authors, underrepresented ethnic groups, and various topics (basic-translational, clinical, malignant, non-malignant) in order to represent broad and diverse perspectives in the field.

The following abstracts will be featured in this session:

Efficient Nanoparticle-Mediated Delivery of Gene Editing Reagents into Human Hematopoietic Stem and Progenitor Cells, Stefan Radtke

Tocilizumab As a Novel Immunomodulatory Regimen for Hemophilia Gene Therapy, Klaudia Kuranda

First-in-Human Clinical Study of a Novel CD7-Targeted Chimeric Antigen Receptor (CAR)-T Cell Therapy for Refractory/Relapsed Mixed Phenotype Acute Leukemia (MPAL), Peihua Lu

Poor Outcome of Patients with COVID-19 after CAR T-Cell Therapy for B-Cell Malignancies: Results from a Multicenter Study on Behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group, Anne Mea Spanjaart

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6), Olalekan Oluwole

Long-Term Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium, Jay Spiegel

Organizer:

Saad S. Kenderian, MD
Mayo Clinic
Rochester, MN

Rodrigo T. Calado, MD, PhD
University of Sao Paulo
Ribeirão Preto, SP, Brazil

Natalie S Grover, MD
University of North Carolina at Chapel Hill
Chapel Hill, NC

back to top

ASH Poster Walk on Financial Toxicity in Hematologic Malignancies


December 16, 2021, 10:00 a.m. - 11:00 a.m.
Virtual Meeting Platform Only

Please view the recorded poster presentations prior to attending this virtual session:

Financial toxicity associated with cancer treatment is increasingly recognized as a significant barrier to quality care, with numerous studies demonstrating this association in solid tumors and blood cancers. With the advent of advanced and targeted therapeutics, long-term survival trends for many hematologic malignancies have seen dramatic increases over the last decade. Often, patients and survivors continue to require chronic maintenance therapies or follow-up outpatient visits, leading to financial burden and toxicity over time.

Over the last few years, studies investigating financial toxicity associated with hematologic malignancies have started moving away from descriptive studies to interventional approaches. The purpose of this Poster Walk is to highlight the timely and interesting studies in this area of high importance to patients with hematologic malignancies, with significant implications in the domains of quality of life, quality of care, and health policy.

The following abstracts will be featured in this session:

Financial Toxicity and Associated Patient-Reported Quality of Life in Plasma Cell Disorders, Walker Schmidt

Productivity Loss and Indirect Costs Among Non-Hodgkin Lymphoma Patients and Their Caregivers, Asher Chanan-Khan

Evaluating the Impact of Therapy Related Healthcare Team Burden on Selection of Novel Therapies for Chronic Lymphocytic Leukemia and Lymphoid Malignancies, Heather Reves

Real-World Analysis of the Clinical and Economic Burden of Later Line in Chronic Myeloid Leukemia Patients in Italy, Luca Degli Esposti

How Important Are in-Person Clinic Visits during Maintenance Therapy for Pediatric Acute Lymphoblastic Leukemia?, Ron Rabinowicz

Impact of the COVID-19 Pandemic on in-Person Visit Rates Among Patients with Hematologic Malignancies in the United States, Gaurav Goyal

Organizer:

Christopher T Su, MD, MPH
University of Michigan
Ann Arbor, MI

Thomas G. Knight, MD
Levine Cancer Institute, Atrium Health
Charlotte, NC

back to top

ASH Poster Walk on Geriatric Hematology: Selecting the Right Treatment for the Patient, Not Just the Disease


Wednesday, December 15, 2021, 5:00 p.m. - 6:00 p.m.
Virtual Meeting Platform Only

Please view the recorded poster presentations prior to attending this virtual session:

Abstracts incorporating the principles of geriatrics into research and clinical practice of caring for older adults with hematologic conditions (both malignant and nonmalignant) are of increasing interest to ASH participants. The ASH Poster Walk on Geriatric Hematology will aggregate these diverse abstracts into a single discussion, allowing key opinion leaders to provide context on the current state of the art in geriatric hematology, covering topics including elderly-specific therapeutic trials, frailty and geriatric assessment.

The following abstracts will be featured in this session:

Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute B-Lymphoblastic Leukemia (INITIAL-1 trial), Matthias Stellijes

Emicizumab Prophylaxis in Persons with Hemophilia A, Aged =50 Years, with Comorbidities – Pooled Data from Four Phase III Studies (HAVEN 1, 3, and 4, and STASEY), Victor Jimenez-Yuste

The Prognostic Implication of Adult Comorbidity Evaluation 27 Score in CML Patients on Tyrosine-Kinase Inhibitors, Kunhwa Kim

Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Interim Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02), Slavisa Ninkovic

Development and Testing of a Lymphoma Clinical Trials Specific Frailty Index: A Secondary Analysis of the LY.12 Clinical Trial, Abi Vijenthira

A Cross-Sectional Analysis of County-Level Social Vulnerability and Physical Frailty Among Adults with Hematological Malignancies, Shakira Grant

Organizer:

Tanya M. Wildes, MD,MSc
Cancer & Aging Research Group
St. Louis, MO

Rebecca L. Olin, MD
University of California, San Francisco
San Francisco, CA

back to top

ASH Poster Walk on Healthcare Quality Improvement


Wednesday, December 15, 2021, 5:00 p.m. - 6:00 p.m.
Virtual Meeting Platform Only

Please view the recorded poster presentations prior to attending this virtual session:

The ASH Committee on Quality (COQ) will host this year’s ASH Poster Walk on Healthcare Quality Improvement, presenting abstracts focused on quality improvement, covering both malignant and non-malignant topics. Quality improvement projects and quality-related outcomes research are integral to helping clinicians and their institutions deliver the most appropriate care in an efficient and effective manner, while avoiding unnecessary tests, procedures and medical errors. The onset of the COVID-19 pandemic has made these issues particularly acute, especially in the context of clinicians seeking to monitor and rapidly implement guidance (including the ASH guidelines on the use of anticoagulation in patients with COVID-19). Quality improvement projects are also increasingly encouraged or required for hematology trainees; highlighting practice-changing work in the field can provide models for trainees and early-career hematologists to follow at their own institutions.

The following abstracts will be featured in this session:

A Resident-Led Quality Improvement Initiative to Optimize Care for Children and Young Adults with Sickle Cell Disease Vaso-Occlusive Pain with Intranasal Fentanyl in the Emergency Department, Wilson Vasconez Samaniego

 Implementation of a Physician Incentivized QI Strategy to Address Time to Parenteral Analgesia in Patients with Voe in the Pediatric Emergency Department, Romy Shane

Successful Quality Improvement Projects to Maximize Prescription Rates and Acceptance of Hydroxyurea Among Patients with Sickle Cell Anemia, Ofelia Alvarez

Improving Value in Emergency Department Management of Deep Vein Thrombosis, Amar Kelkar

Prospective Study to Reduce Clostridium Difficile Infection in Patients Receiving Autologous Stem Cell Transplantation, Samuel Maldonado

Improving Feedback for Hematology and Oncology Fellows Via Virtual Workshops: Sustainability Analysis, Sarah Sewaralthahab

Organizer:

Yulia Lin, MD
Sunnybrook Health Sciences Centre
Toronto, ON, Canada

Michael Keng, MD
University of Virginia
Charlottesville, VA

back to top

ASH Poster Walk on Natural Killer Cell-Based Immunotherapy


Wednesday, December 15, 2021, 5:00 p.m. - 6:00 p.m.
Virtual Meeting Platform Only

Please view the recorded poster presentations prior to attending this virtual session:

This poster walk would aim to highlight recent advance in use of natural killer (NK) cells for improved cancer therapies. NK cell-based therapies are now being pursued from many sources including cord blood, peripheral blood and iPSCs. There are also agents (Bikes, Trikes, cytokines such as IL15, etc) to stimulate endogenous NK cells that are being developed. This poster walk would highlight both pre-clinical and clinical studies that show the progress in this field.

The following abstracts will be featured in this session:

iPSC-Derived Natural Killer Cells and Macrophages Synergistically Kill Acute Myeloid Leukemia Blasts, Benjamin Goldenson

Phase I Study of FT516, an Off-the-Shelf iPSC-Derived NK Cell Therapy, in Combination with Rituximab in Patients with Relapsed/Refractory B-Cell Lymphoma, Krish Patel

Using NK-Derived Exosomes to Treat Leukemia, Aladin Samara

Cryopreserved CAR-like NK Cells Pre-Complexed with the CD30/CD16A Bispecific Innate Cell Engager (ICE®) AFM13 for the Treatment of CD30+ Malignancies, Joachim Koch

FLT3 OR CD33 NOT EMCN Logic Gated CAR-NK Cell Therapy (SENTI-202) for Precise Targeting of AML, Brian Garrison

Organizer:

Dan S Kaufman, MD,PhD
University of California San Diego
La Jolla, CA

Jeffrey S. Miller, MD
University of Minnesota
Minneapolis, MN

back to top

ASH Poster Walk on Pediatric Non-Malignant Hematology Highlights


Wednesday, December 15, 2021, 5:00 p.m. - 6:00 p.m.
Virtual Meeting Platform Only

Please view the recorded poster presentations prior to attending this virtual session:

The ASH Poster Walk on Pediatric Non-malignant Hematology will review the poster highlights for new and emerging research that you must see in pediatric hematology -- including thrombosis/hemostasis, immune cytopenias, hemoglobinopathies, and other rare hematologic pediatric conditions. Join others interested in pediatric hematology and network with them as well as meeting the authors of these selected abstracts. Learn about where cutting edge research is in this field in 2021; and we hope you leave with exciting research questions (and maybe collaborations) of your own as a result!

The following abstracts will be featured in this session:

The Role of PF4 Antibodies in Pediatric Sars-Cov-2 Infections, Michele Lambert

Use of Red Blood Cell Phenotypes for Second Line Therapy Selection in Sickle Cell Disease, Celeste Kanne

Evaluating Clinical Outcomes and Potential Prognostic Factors Among 308 Children and Adolescents with Immune Thrombocytopenia (ITP): An 11-Year Retrospective Cohort Study, Xiaopei Zeng

Molecular and Biological Characterization of Transient Antithrombin Deficiency: A New Concept in Congenital Thrombophilia, Maria Eugenia de la Morena-Barrio

The Impact of the “Super Coombs” Test on Patient Management and Outcomes at a Large Tertiary Care Center: A Retrospective Review, Mamie Thant

Assessment of Cardiac Abnormalities in Sickle Cell Disease Patients Using Cardiac Magnetic Resonance Imaging (CMR), Cara Mortrin

Organizer:

Tiffany Lin Lucas, MD
University of California, San Francisco
San Francisco, CA

Alexandra Power-Hays, MD
Cincinnati Children's Hospital Medical Center
Cincinnatti, OH

back to top

ASH Poster Walk on the Spectrum of Hemostasis and Thrombosis Research


December 16, 2021, 5:00 p.m. - 6:00 p.m.
Virtual Meeting Platform Only

Please view the recorded poster presentations prior to attending this virtual session:

Non-malignant hematology covers a broad range of topics. The purpose of the ASH Poster Walk on the Spectrum of Hemostasis and Thrombosis Research is to highlight a clinical and a translational/basic science abstract in hemostasis, thrombosis, and platelet disorders to foster discussion across disciplines and to encourage young investigators to pursue this career path. Trainees/junior faculty will have a unique opportunity to meet with leaders in the field of hemostasis and thrombosis, get exposure to various topics within non-malignant hematology, and to learn how to interpret the data presented in a poster.

The following abstracts will be featured in this session:

Predicting Chronic Immune Thrombocytopenia in Pediatric Patients at Disease Presentation: Leveraging Clinical and Laboratory Characteristics Via Machine Learning Models, Derek MacMath

Prevention of Fetal/Neonatal Alloimmune Thrombocytopenia in a Preclinical Model By Monoclonal Anti-HPA-1a Antibody Prophylaxis: Structural and Functional Properties of Antibody Variant Isoforms, Trude Mortberg

The Anticoagulant Properties of Protamine: New Mechanistic Insights into Its Interaction with Factor V, Teodolinda Petrillo

Bleeding in Patients with Clinically Severe Von Willebrand Disease: Interim Analysis of Athn 9: A Natural History Study for People with Severe Von Willebrand Disease (VWD), Robert Sidonio

Extra-Splenic Role of B Cell Activating Factor Blockade in Prevention of Factor VIII Inhibitors, Bhavya Doshi

Organizer:

Lisa Baumann Kreuziger, MD
Versiti, Blood Research Institute
Milwaukee, WI

Janna Journeycake, MD, MSCS
University of Oklahoma Health Sciences Center
Oklahoma City, OK

back to top

ASH Poster Walk on What's Hot in Sickle Cell Disease


Wednesday, December 15, 2021, 10:00 a.m. - 11:00 a.m.
Virtual Meeting Platform Only

Please view the recorded poster presentations prior to attending this virtual session:

Sickle cell disease (SCD) affects 100,000 people living in the US and 250-300,000 births annually worldwide. Despite its frequency, the natural history of SCD and its complications remain poorly understood. Over the past decade, clinical research has led to much progress in disease management, identifying novel therapeutic targets and FDA approval of two new therapies, crizanlizumab and voxelotor, in the fall of 2019. For the past 18 months, SCD research has been over-shadowed by the COVID-19 pandemic and many hematologists not directly involved in this work may not be up to date on recent findings. This compounds the known health care disparities in this field. We plan to highlight six poster abstracts focused on clinical research in SCD to review critically and discuss with the authors SCD to increase dissemination of their data. The organizers of this poster walk bring expertise in adult and pediatric hematology and pulmonary/critical care to the discussion and represent leadership from two major sickle cell centers in the United States.

The following abstracts will be featured in this session:

Stroke without Cerebral Vasculopathy in Sickle Cell Disease Children: Which Causes? Which Treatment?, Sarah Liane Linguet

The Burden of Atrial Fibrillation in Sickle Cell Disease, Chinonso Ukeje

Vitamin D Levels: Associations with Acute Pain Events and Self-Reported Pain in Children with Sickle Cell Disease, Latika Puri

Early Evaluation of the Use of Crizanlizumab in Sickle Cell Disease: A National Alliance of Sickle Cell Centers Study, Julie Kanter

Cognitive Profile of Adults with Sickle Cell Disease - Cluster Analysis, Maryline Couette

Nonmyeloablative Transplant for Sickle Cell Disease Does Not Lead to Kidney Dysfunction Post-HSCT, Emily Limerick

Organizer:

Elizabeth Klings, MD
Boston University Sch. of Med. The Pulmonary Center, R-304
Boston, MA

Andrew D. Campbell, MD
Childrens National Hospital
Silver Spring, MD

Sherif M. Badawy, MD
Ann and Robert Lurie Children's Hospital
Chicago, IL

Melanie E. Fields, MD
Washington University School of Medicine
St. Louis, MO